Predict your next investment

Genextra company logo
Corporation
HEALTHCARE | Biotechnology
genextra.it

See what CB Insights has to offer

Investments

6

Portfolio Exits

1

Partners & Customers

1

About Genextra

Genextra is a private biopharmaceutical company committed to the development of innovative therapeutics primarily for the cure of age-related and metabolic diseases and of cancer

Genextra Headquarter Location

Via Privata Giovannino De Grassi, 11

Milan, 20123,

Italy

+39 02 3651 5110

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Genextra Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Genextra Rank

Latest Genextra News

InnovHeart Closes Series B Financing of 20 Million Euros

Sep 29, 2020

InnovHeart Closes Series B Financing of 20 Million Euros InnovHeart Closes Series B Financing of 20 Million Euros Money will be used to complete the First-in-Human clinical evaluation of the company’s Saturn TMVR system. Business Wire09.29.20 InnovHeart s.r.l. , a developer of transcatheter mitral valve replacement (TMVR) systems for the treatment of mitral valve disease, has closed a €20 million round of equity financing. Founded in 2015 by Giovanni Righini, a 30-year veteran of the heart valve industry, the company maintains offices outside Milan, Italy, and Boston, Mass. Proceeds from the financing will be used to complete the First-in-Human clinical evaluation of the company’s unique Saturn TMVR system using a trans-apical approach. The round will also allow InnovHeart to finalize the development of the trans-septal delivery system, which uses the same Saturn valve technology. The Series B round was raised from existing investor  Genextra , which has been the sole investor since 2015, and a syndicate led by Panakes Partners, with CDP Venture Capital and Indaco Venture Partners joining the round. “With millions of patients suffering from severe Mitral Regurgitation, there remains an unmet clinical need for a safer, less-invasive treatment that has the potential to eliminate MR. With the support of Genextra and our new investors in this Series B financing, we are excited to be able to take the Saturn TMVR into the clinic and begin providing a solution for these patients,” said Keith D. Dawkins M.D., chairman of the InnovHeart Board of Directors and former executive vice president and global chief medical officer at Boston Scientific Corp. In support of this Series B investment, Barbara Castellano will be joining the InnovHeart Board of Directors to represent Panakes Partners, bringing with her a long background in cardiovascular devices from her experience at Sorin (now LivaNova). “The innovative design of Saturn TMVR and its unique approach to delivering and anchoring the implant has the potential to provide significant advantages over first generation systems and the ability to treat a large and heterogeneous patient population,” said Castellano. “Genextra is eager to continue supporting InnovHeart through the significant milestones the company is about to achieve, bringing the novel Saturn valve to trans-apical and trans-septal clinical testing,” said Federica Draghi, investment director at Genextra. PRNewswire 09.28.20 GlobeNewswire 09.25.20 MedTech Innovator 09.24.20 PR Newswire 09.24.20 Business Wire 09.23.20 Medtronic 09.23.20 Business Wire 09.23.20 PR Newswire 09.22.20 Abbott 09.21.20 Business Wire 09.21.20 Business Wire 09.18.20 PR Newswire 09.16.20 Business Wire 09.14.20 Business Wire 09.14.20 Johnson & Johnson 09.10.20

Genextra Investments

6 Investments

Genextra has made 6 investments. Their latest investment was in InnovHeart as part of their Series B on August 8, 2020.

CBI Logo

Genextra Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

8/7/2020

Series B

InnovHeart

$23.57M

Yes

3

4/24/2018

Unattributed VC

Subscribe to see more

$99M

Subscribe to see more

10

8/10/2012

Series C

Subscribe to see more

$99M

Subscribe to see more

10

1/14/2010

Series B

Subscribe to see more

$99M

Subscribe to see more

10

7/7/2008

Series A - II

Subscribe to see more

$99M

Subscribe to see more

10

Date

8/7/2020

4/24/2018

8/10/2012

1/14/2010

7/7/2008

Round

Series B

Unattributed VC

Series C

Series B

Series A - II

Company

InnovHeart

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$23.57M

$99M

$99M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

3

10

10

10

10

Genextra Portfolio Exits

1 Portfolio Exit

Genextra has 1 portfolio exit. Their latest portfolio exit was Intercept Pharmaceuticals on October 11, 2012.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

10/11/2012

IPO

$991

1

Date

10/11/2012

Exit

IPO

Companies

Valuation

$991

Acquirer

Sources

1

Genextra Partners & Customers

1 Partners and customers

Genextra has 1 strategic partners and customers. Genextra recently partnered with Evotec on July 7, 2006.

Date

Type

Business Partner

Country

News Snippet

Sources

7/18/2006

Partner

Evotec

Germany

Evotec - Creating integrated drug discovery innovation alliances DAC Selects Evotec as Strategic Partner for a Drug Discovery Collaboration on the HSP90 Cancer Target.

Following due diligence DAC has decided to collaborate with Evotec with the aim of improving the potency and selectivity of the identified compounds .

1

Date

7/18/2006

Type

Partner

Business Partner

Evotec

Country

Germany

News Snippet

Evotec - Creating integrated drug discovery innovation alliances DAC Selects Evotec as Strategic Partner for a Drug Discovery Collaboration on the HSP90 Cancer Target.

Following due diligence DAC has decided to collaborate with Evotec with the aim of improving the potency and selectivity of the identified compounds .

Sources

1

Genextra Team

2 Team Members

Genextra has 2 team members, including current Chief Executive Officer, Paolo Fundarò.

Name

Work History

Title

Status

Francesco Micheli

Founder

Current

Paolo Fundarò

FastWeb

Chief Executive Officer

Current

Name

Francesco Micheli

Paolo Fundarò

Work History

FastWeb

Title

Founder

Chief Executive Officer

Status

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.